US FDA Approves New Sunscreen Ingredient After 20 Years, Blocks Both UVA and UVB
Broad-Spectrum Protection with a Single Chemical Filter
No White Cast and Low Skin Absorption
DSM Holds 18-Month Monopoly... Launch Expected This Year
The U.S. Food and Drug Administration (FDA) has added the new ultraviolet (UV) filter ingredient 'Bemotrizinol' to the list of over-the-counter (OTC) active ingredients, which can block both UVA and UVB rays with a single ingredient. This is the first newly approved sunscreen ingredient in the U.S. in more than 20 years since the late 1990s. Until now, chemical filters sold in the U.S. could only block either UVA or UVB, requiring multiple ingredients to be mixed together, while mineral filters such as zinc oxide and titanium dioxide, which block both types of rays, were limited by the white cast effect they left on the skin. With the introduction of Bemotrizinol, which enables broad-spectrum protection with a single ingredient, the product landscape in the U.S. sun care market is expected to change.
According to the FDA on June 9 (local time), Bemotrizinol has been recognized as a substance that is safe and effective (GRASE) for use in sunscreens for adults and children aged six months and older. Bemotrizinol blocks both UVA and UVB rays at the same time, while its absorption into the body through the skin is low. Unlike existing chemical filters, which break down when exposed to sunlight and must be reapplied frequently, Bemotrizinol also demonstrates high photostability.
According to the American Academy of Dermatology, UVA causes skin aging and wrinkles, while UVB causes sunburn. The Skin Cancer Foundation notes that both types of rays can cause skin cancer. To achieve effective sun protection, it is essential to have broad-spectrum coverage that blocks both UVA and UVB rays.
The delayed introduction of Bemotrizinol into the U.S. market is due to differences in regulatory classification. The U.S. classifies sunscreens as over-the-counter drugs requiring strict clinical trials, whereas Europe, Korea, and other regions treat them as cosmetics, allowing for faster adoption of new technologies. As a result, Bemotrizinol has been used for decades in Europe, Australia, and Asia, but American consumers have had to rely solely on conventional chemical filters and mineral-based products until now.
U.S. Secretary of Health and Human Services Robert Kennedy Jr. stated that, as pledged in the Trump Administration's 'MAHA' strategy report, a new sunscreen ingredient has been introduced to the U.S. market for the first time in over 20 years. He added that this move will increase competition in the sunscreen market and enhance consumer confidence.
Netherlands-based ingredient manufacturer DSM-Firmenich has secured an 18-month exclusive sales right in the U.S. OTC sunscreen market with this approval. Sunscreens containing Bemotrizinol (marketed as Parsol Shield) are expected to be released by the end of the year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The K-beauty industry, which enjoys popularity in the U.S. market, also sees this approval as a turning point for targeting the American sun care market. However, opening the door to ingredient use does not mean that sunscreens produced in Korea can be exported as they are. In Korea, sunscreens are classified as functional cosmetics, but in the U.S. they are considered over-the-counter drugs, so companies must develop and register products in compliance with OTC regulations and manufacture them in facilities approved by the FDA under current Good Manufacturing Practice (cGMP) standards. The fact that DSM-Firmenich holds exclusive supply rights for the ingredient for 18 months is also a variable.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.